Artemisinin
Upcoming SlideShare
Loading in...5
×
 

Artemisinin

on

  • 291 views

 

Statistics

Views

Total Views
291
Views on SlideShare
291
Embed Views
0

Actions

Likes
0
Downloads
8
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

Artemisinin Artemisinin Document Transcript

  • Epidemiology of Malaria drug-resistant malaria is a rapidly spreading global health threat Malaria is a public health problem today in more than 90 countries, inhabited by 2,400 million people – 40% of the world’s population An estimated 300 to 500 million cases each year cause 1.5 to 2.7 million deaths, more than 90% of which occur in children under age 5 in Africa. Malaria kills one child every 30 seconds Progresses made in the last 50 years in restricting the geographical areas affected by malaria are being eroded recently, due to changes in land use, global climate changes, armed conflicts/movement of refugees, easy international travel and development of multi-drug resistant strains of parasite. The vast majority of areas of endemic malaria show resistance to chloroquine (the oldest, cheapest treatment). Resistance to sulfadoxine-pyrimidine is emerging in most affected areas. Resistence to mefloquine has been observed in South-east Asia (areas of multi-drug resistance) No malaria Malaria present only in small, remote areas. No chloroquine-resistant P.falciparum. Malaria transmision areas Intermediate malaria risk, no chloroquine-resistant strains of P.falciparum. Multidrug resistance areas Intermediate malaria risk, but chloroquine-resistance of P.falciparum is Chloroquine resistance areas conf irmed. Malaria-f ree islands Sulf adoxine –py rimethamine resistance areas High risk area f or chloroquine-resistant Plasmodium falciparum. No clinically relevant resistance has been observed with artemisinin and related derivatives 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10